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Abstract 
 
TCF11 is a regulatory transcription factor belonging to the CNC-bZIP family. The 
specific biological function of this protein is still unknown. However, knockout 
studies in mice have revealed its importance during embryo development, and other 
studies have also displayed its involvement in the cell’s defense system against 
oxidants and carcinogens. The transactivating ability and intracellular localization of 
TCF11 and the isoform Nrf1 have been studied in cells using high expression 
plasmids. Due to the recent findings that over-expression of TCF11 in transfected 
cells caused an increase in cell mortality, the need for lower TCF11/Nrf1 expressing 
plasmids emerged. An additional reason for constructing the low expression plasmids 
was to study the localization and transactivating abilities of the proteins at levels 
closer to the endogenous situation. The transactivating ability was estimated by 
measuring the luciferase activity in COS-1 cells transiently co-transfected with a 
reporter plasmid and a high or low TCF11/Nrf1 expressing plasmid. The intracellular 
localization images were acquired by means of epifluorescence and confocal 
microscopy. The initial low expression constructs proved unsuitable due to the empty 
vector’s ability to cause indirect activation of the reporter plasmid. The second set of 
constructs were low expression plasmids that permitted verification of the nuclear 
detainment of Nrf1. However, further intracellular compartmentalization could not be 
detected for either Nrf1 or TCF11. In addition, TCF11 displayed a higher 
transactivating ability compared to Nrf1. 
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1 Introduction 
 
Inside the nucleus of virtually every cell in a eukaryotic organism is a complex set of 
hereditary instructions encoded in the DNA (deoxyribonucleic acid). Within the DNA 
are short segments called genes that are transcribed into RNA (ribonucleic acid), 
which in turn is translated into proteins. Proteins are macromolecules that act as the 
cell’s building blocks and carry out most of the organism’s cellular functions. The 
differentiation between cells in a multicellular organism is the result of selective 
expression of genes, allowing for the creation of highly specialized phenotypically 
distinct cells. This selectivity is generally accomplished by controlling the initiation 
and inhibition of DNA to RNA transcription, which makes this control system one of 
the most important mechanisms of cellular regulation. One group of proteins that are 
key factors in transcription regulation is known as the regulatory transcription factors. 
The TCF11 protein studied in this thesis belongs to this group. 
 
1.1 Transcription initiation in eukaryotic cells 
 
The transcription of protein-coding genes in multicellular organisms is a highly 
complex, multi-level process. In general, transcription is thought to be initiated 
through the binding of regulatory transcription factors to activating gene sequences. In 
turn, these activators recruit the chromatin modifying complexes and the transcription 
initiation apparatus, allowing for transcription elongation to begin (1). The intricacies 
of this process will be reviewed in more detail. 
 
1.1.1 Chromatin modification 
 
Inside the nucleus the DNA is arranged into chromatin, a nucleoprotein complex 
consisting of nucleosomes, or DNA tightly packed around a histone octamer. This 
configuration is essential for the compact packaging of the genome, but may at the 
same time repress the binding of transcription-associated factors to their respective 
target sequences, thereby obstructing transcription (1). However, several activating 
transcription factors that have the capability of recognizing upstream activating 
sequences within the chromatin can alleviate this repression (2). These factors possess 
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the ability to recruit protein complexes that alter the configuration of the chromatin. 
The altering complexes can be divided into two main classes: chromatin remodeling 
and chromatin modifying. The chromatin remodeling complexes, like SWI/SNF and 
NURF, remodel the chromatin by breaking and reforming the histone-DNA contacts 
in an ATP-dependent manner (3,4). The chromatin modifying complexes, on the other 
hand, can modify the histones through acetylation/deacetylation, phosphorylation, 
methylation and ubiquitination (1). As an example, the acetylation of histones disrupts 
the chromatin and is completed by histone acetyl transferases (HATs, e.g. CBP/p300 
and P/CAF) (5,6). Deacetylation by means of histone deacetylases (HDACs, e.g. 
HDAC1), on the other hand, has the opposite effect (7). Both the remodeling and the 
modifying complexes have been shown to be crucial for transcription initiation (3). 
 
1.1.2 The basal transcription machinery 
 
Once the chromatin is disrupted, several activating transcription factors, like VP16 
and p45 NF-E2 (8,9), have been shown to subsequently recruit and stabilize the 
transcription apparatus to the promoter (1). At the base of this basal transcription 
machinery termed the preinitiation complex (PIC), is an enzyme called RNA 
polymerase II (Pol II), one of the three known RNA polymerases (10). This mRNA-
transcribing enzyme requires the recruitment of several additional factors in order for 
transcription to be initiated. Among the necessary factors are the general transcription 
factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (11), which have been 
shown to; aid in the recruitment of RNA Pol II to the promoter, the melting of the 
DNA helix, and also to assist in the following elongation (12). There are two possible 
models explaining the manner in which the PIC assembles, the ordered assembly 
model and the holoenzyme model (Fig. 1-1). The ordered assembly was the initial 
model based on a sequential recruitment of the required factors. The assembly is 
initiated by the binding of GTF TFIID to the TATA box, an A/T-rich promoter 
element. TFIID is a multi-subunit factor composed of the TATA-binding protein 
(TBP) and the TBP-associated factors (TAFs). The TFIIA coactivator subsequently 
binds to the TFIID-DNA complex, which is stabilized by the binding of the TFIIB. 
The resulting complex acts as a platform for the recruitment of RNA Pol II and TFIIF. 
The PIC is completed by the GTFs TFIIE and TFIIH.  
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The more recent holoenzyme model, on the other hand, suggests the presence of a 
pre-assembled complex where several of the GTFs are associated with RNA Pol II 
(13,14). This model suggests that the formation of the TFIID-TFIIA-DNA complex is 
followed by the recruitment of the holoenzyme, thus forming the PIC. The 
transcription initiation, including the chromatin modification and the two models of 
PIC assembly, is shown in figure 1-1. 
 
 
Figure 1-1 A schematic representation of transcription initiation. The representation includes the 
binding of transcription activators to the chromatin, the recruitment of the chromatin remodeling (e.g. 
SWI/SNF) and modifying (e.g. CBP) complexes, leading up to the two different models of PIC 
assembly. (This figure is modified from (13) and (15)). 
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1.1.3 Transcription elongation 
 
Once the PIC is stably assembled on the promoter, elongation can be activated. The 
switch from initiation to elongation occurs through a number of events, including the 
melting of DNA to form an open complex, promoter clearance, and the disassociation 
of various factors from the PIC, thus turning it into an elongation enzyme (1,13). 
Regulatory transcription factors have been shown to be involved in the switch from 
initiation to elongation (16). As an example, the GTF TFIIF has been suggested to 
require the transcription factor c-Myc in order to stimulate the elongation process by 
lowering the frequency of abortive initiation (17). Another GTF, the TFIIH, aids in 
the conversion of PIC into an elongation enzyme through phosphorylation of the C-
terminal tail of RNA Pol II. This process is thought to be mediated by the presence of 
TFIIE and the regulatory transcription factor GAL11 (18). 
 
1.2 Regulatory transcription factors 
 
The regulatory transcription factors modulate transcription of target genes by their 
binding to specific upstream regulating sequences. As mentioned earlier, these factors 
can affect several steps in the process of transcription, including chromatin 
remodeling, PIC formation, promoter clearance and elongation. The factors may not 
only aid in the activation of transcription, but some also repress it, while others can 
still do both. The factors normally have two functional domains: one DNA binding 
domain for recruitment to DNA, and one activating or repression domain for 
transcription regulation (19). The transcription factors are divided into families on the 
basis of their DNA-binding domains. The four most common are: 1) Helix-turn-helix, 
2) zinc-coordinating, 3) helix-loop-helix and 4) leucine-zipper (20). 
 
The activating domains (AD) are responsible for the interaction with factors of the 
transcription machinery and thereby aid in transcription activation. These domains are 
not as well defined as the DNA-binding domains because they lack a defined 
secondary structure in the absence of their target proteins. The ADs can normally be 
placed within one of the following groups: 1) Acidic, 2) glutamine-rich and 3) 
Section 1                                                                                                       Introduction 
 
5
proline-rich. However, not all ADs fit into these categories and several novel motifs 
have been suggested, such as the proposed leucine-rich acidic region (21). 
Some regulatory transcription factors may also repress transcription in a gene-specific 
manner. Generally, these factors are thought to inhibit the activators from binding to 
the promoter, suppress the function of a promoter-bound activator, or hinder the 
assembly of the transcription machinery (13). However, the understanding of 
transcriptional repression is far less advanced compared to that of transcriptional 
activation. 
 
1.2.1 bZIP transcription factors 
 
The bZIP superfamily of transcription factors is a group of proteins found in virtually 
all eukaryotic organisms (22). These transcription factors are obligate homo- or 
heterodimers, and are characterized by having a basic-region leucine zipper domain 
(bZIP) located at the C-terminal end of a single -helix. The bZIP domain contains 
two structural features, the dimerization and the DNA-binding domains. The 
dimerization domain consists of a heptad repeat of leucines, or other hydrophobic 
amino acids, which creates an amphipathic helix. Dimerization occurs by means of 
interactions between the hydrophobic residues of two monomers, creating a 
superimposing coiled-coil structure referred to as a zipper (see Fig. 1-2). The adhesion 
is further influenced by the electrostatic attraction and repulsion of polar residues 
flanking the hydrophobic interaction surface of the helixes (23).  
 
The major function of dimerization is to bring together the DNA-binding regions of 
each monomer, allowing the resulting dimer to bind to the target sites. This is a result 
of the target sites being of a palindromic nature, requiring a dimeric binding domain 
where each monomer binds to their respective half site. The DNA-binding domain 
consists of basic amino acids immediately preceding the dimerization domain. 
Examples of the bZIP transcription factors are GCN4, c-Jun and c-Fos (23). Notably, 
dimers of the Jun and Fos gene family create a protein complex known as the 
activator protein-1 (AP-1) transcription factor. This complex, consisting of either Jun-
Fos or Jun-Jun dimers, has been shown to play an important role in regulating cellular 
proliferation and differentiation (24). 
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Figure 1-2 Illustration of a bZIP transcription factor (GCN4) bound to DNA.  Leucine residues 
are marked in red. Illustration taken from (22). 
 
1.2.2 CNC-bZIP 
 
TCF11 belongs to a subset of the bZIP superfamily of proteins termed the CNC-bZIP 
transcription factors (25). This group of proteins, which also include p45 NF-E2, 
Nrf2, Nrf3, Bach1 and Bach2 (26), (27-29) share the features of the bZIP type 
proteins, but have an additional conserved structural domain, termed the Cap’n’collar 
(CNC)-domain. This domain was first noted in the Drosophila Melanogaster CNC 
gene, which is required for labial and mandibular development (30). The CNC domain 
immediately precedes the bZIP DNA-binding domain, but its function is unknown. In 
addition to containing the CNC sequence, members of this family show strong 
similarity in their basic DNA-binding domain, binding the NF-E2/AP-1 element with 
similar specificity. The consensus sequence is T/CGCTGAG/CTCAT/C, with the AP-1 
site underlined. This DNA binding site is located in the promoter of numerous genes 
in the human genome, one being in the promoter regulating the erythroid-specific 
porphobilinogen deaminase (PBGD) gene (31). The transcription factors belonging to 
this family are presented below, with special reference to TCF11. A schematic 
representation of the factors in the CNC-bZIP family is shown in figure 1-3. 
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Figure 1-3 A schematic representation of the CNC-bZIP family of transcription factors. The 
domains and size expressed in amino acids (aa) are indicated. 
 
1.2.2.1 p45 NF-E2 
 
p45 NF-E2 is an erythroid-tissue specific transcription factor (32) that has a N-
terminally proline-rich transactivation domain in addition to the CNC-bZIP domain 
(Fig. 1-3). This protein dimerizes with one of the three widely expressed small 
musculoaponeurotic fibrosarcoma proteins (Maf F, MafG or MafK) (33), forming the 
heterodimeric nuclear factor-erythroid 2 (NF-E2) complex. This dimer activates 
transcription by binding to the NF-E2/AP-1 site, and was originally identified as a 
complex activating PBGD and -globin gene expression (31,34). The NF-E2 complex 
was therefore suggested to be a key regulatory element controlling pathways of heme 
and globin synthesis, leading to a balanced production of the hemoglobin 
components. However, a study showed that p45 NF-E2 knock-out mice were only 
slightly anemic, suggesting that a different bZIP factor could somewhat replace p45 
NF-E2 in the NF-E2 complex (35). The same study reported a striking decrease in the 
platelet count, a finding that was later attributed to p45 NF-E2’s involvement in the 
regulation of the thromboxane synthase protein, an enzyme essential for platelet 
formation and function (36). In addition, the activity of p45 NF-E2 has been shown to 
be elevated through interactions with co-factors like TAFII130 and CBP (9,37). 
Furthermore, p45 NF-E2 possesses the ability to stimulate histone acetylation 
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mediated by CBP. This modification results in an increase in the ability to bind DNA 
and also an elevation of target gene expression (38). 
 
1.2.2.2 Nrf2 
 
Nrf2 is a ubiquitously expressed CNC-bZIP transcription factor having a N-terminally 
acidic transactivation domain (Fig. 1-3). Its protein sequence contains regions of high 
similarity to that of p45 NF-E2, and was therefore termed NF-E2 related factor 2 
(Nrf2) (39). In addition to having similar DNA-binding abilities, Nrf2 has also been 
shown to dimerize with the small Maf proteins. However, in contrast to p45 NF-E2, 
the activity of Nrf2 decreased as a result of dimerization (40).  
 
Nrf2 is linked to the regulation of detoxification and antioxidant proteins in cells. It 
appears as though Nrf2 is essential for the expression of phase two enzymes, which 
are necessary to produce antioxidants like glutathione (41). Nrf2 binds and activates 
through the antioxidant response elements (ARE), a binding site with strong sequence 
similarity to the NF-E2/AP-1 site. An ARE recognized by Nrf2 is located in the 
promoter of the -glutamylcysteine synthetase gene (-GCS), encoding for the rate-
determining enzyme involved in the synthesis of glutathione (42).  
 
1.2.2.3 Nrf3  
 
The third NF-E2 related factor, Nrf3, was discovered in 1999 (28) (Fig. 1-3). This 
transcription factor has been detected in low levels in various tissues and has recently 
shown an elevated expression in Hodgkin and Reed/Sternberg (HRS) cells, which are 
unique to the Hodgkin lymphoma (HL) malignancy (43). Little is known about the 
function of Nrf3, but transient transfections have indicated that homodimers of the 
protein repress reporter induction (28). Nrf3 may also form a heterodimer with MafK, 
which appear to activate reporter induction through the binding of Maf recognition 
elements (MARE). 
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1.2.2.4 Bach1 and Bach2 
 
Bach1 and Bach2 differ slightly from the other CNC-bZIP proteins in that they have 
an additional structure referred to as the “broad complex tramtrack bric-a-brac” 
(BTB) domain (29) (Fig. 1-3). This N-terminally located domain is found in a variety 
of DNA-binding proteins and has been shown to be of importance in transactivation 
and chromatin remodeling (44,45). Transcription factor Bach1 appears to be 
ubiquitously expressed, while Bach2 has only been detected in developing B-cells and 
neural cells (46). In addition, Bach2 expressed in neural cells appears to have an 
additional serine-rich domain of unknown function that is not present in B-cell-
expressed Bach2. Like the p45 NF-E2 and Nrf proteins, these transcription factors can 
bind to the NF-E2/AP-1 site as either monomers or by forming dimers with the small 
Maf proteins. As an example, Bach1 dimerizing with MafK has been reported to 
repress transcription of the target genes (29). This heterodimer is associated with the 
regulation of heme oxygenase-1 (HO-1), a protein shown to protect cells from 
oxidative stress associated with high levels of heme. (47). The function of Bach2 is 
also stress-related and evidence has shown that its presence can induce apoptosis in 
response to oxidative stress (48).  
 
1.2.2.5 TCF11 
 
Transcription factor 11 (TCF11) is a ubiquitously expressed protein that was first 
identified by the Kolstø group in 1994 (25). This protein has three domains in 
addition to the CNC-bZIP domain, including an N-terminal acidic domain, an internal 
acidic domain, and an internal serine-rich domain (Fig. 1-3). The N-terminal acidic 
region has been found to function as TCF11’s transactivation domain (49). For full 
transactivation to occur, however, the serine-rich domain has been shown to be 
essential, which is thought to be due to the several potential phosphorylation sites 
within this region. The internal acidic domain, however, has not yet been found to be 
crucial to the transactivating ability of the protein. Additional regions of importance 
in the TCF11 protein are the nuclear localization signal (NLS) located in the basic 
bZIP region, and the nuclear export signal (NES) located in the N-terminal 
transactivation domain (50). 
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Parallel to the discovery of TCF11, there were other research groups that isolated two 
additional protein isoforms of the same gene. TCF11 is therefore also referred to as 
Nrf1 (NF-E2 related factor 1 (51)) and LCR-F1 (Locus Control Region-Factor 1 (52)) 
(Fig. 1-4). The Nrf1 isoform is a result of alternative splicing (Section 1.3.1) within 
the gene, causing the loss of a 30 aa’s segment in the N-terminal transactivation 
domain. The removed leucine rich sequence contains a NES-signal, and studies have 
indicated that Nrf1 therefore lacks the ability to be exported from the nucleus (50). 
Alternative splicing within the transactivation domain produces several other 
isoforms, ranging from 728 to 769 amino acid residues in size (25).  
 
TCF11 isoforms are also created through alternative translation initiation (Section 
1.3.1). Because the first initiation site in the TCF11 transcript is non-optimal, the 
translation is initiated from an internal initiation site. LCR-F1 is produced in this 
manner, resulting in a 447 aa’s isoform lacking the N-terminal transactivation domain 
(25,52). As could be expected due to the absence of this domain, this isoform displays 
strict nuclear localization (50), and transient transfections have failed to detect any 
activity (49).  
 
 
Figure 1-4 A schematic representation of TCF11, Nrf1 and LCR-F1. The domains, deletion and 
size expressed in aa’s are indicated. 
 
A common feature of the CNC-bZIP family of proteins appears to be the ability to 
dimerize with the small Maf proteins. TCF11 is no different, forming heterodimers 
with Maf that show higher affinity to the NF-E2/AP-1 site compared to the TCF11 
homodimer (53). ATF4 (personal communication, A-B. Kolstø) and the Jun proteins 
(54) have also been suggested to be potential dimerization partners of TCF11. 
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As with all of the CNC-bZIP factors, studies have shown that TCF11 can bind and 
transactivate through the NF-E2/AP-1 site (55). However, TCF11 has not yet been 
detected to have a direct effect on the mRNA expression of genes under the control of 
this site (i.e. PBGD and -globin). TCF11 has also been reported to activate through 
ARE-elements (56), as seen for Nrf2 (54,57). These NF-E2 like sequences are found 
in the promoter regions of genes associated with the cellular defense system against 
free radicals and toxic compounds. Two examples of these genes are the glutathione 
synthase (GSS) and the previously mentioned -GCS. These enzymes are necessary 
for the synthesis of glutathione, which is a ubiquitously expressed non-protein 
sulphydryl involved in the maintenance of the intracellular redox balance and 
elimination of free radicals (58). Studies have indicated that TCF11 plays an 
important role in the regulation of both enzymes, and subsequently the indirect 
regulation of glutathione (56). In addition, TCF11/Nrf1 is suggested to regulate the 
detoxifying enzymes NAD(P)H:quinone oxidoreductase (NQO1) and glutathione s-
transferase (GST) (54,57). In view of these findings, TCF11 appears to be an essential 
factor in the cell’s defense system against oxidants and carcinogens. Interestingly, 
recent studies present evidence that, although TCF11 and Nrf2 do not have identical 
functions in their response to oxidative stress, they have the ability to somewhat 
compensate for each other and coordinate their regulating ability (59). 
 
TCF11 has also been found to be an essential protein in the embryo development. 
Studies on mouse embryos unable to express TCF11 proved to be fatal at an early 
stage. One study attributed the fatality to the lack of mesoderm formation, suggesting 
that TCF11 is essential for gastrulation (60). A different study found that the TCF11 
deficiency caused anemia, and that TCF11 is involved in the early stages of red blood 
cell production (erythropoiesis) in the liver (61). Recent studies ascribed the reduced 
erythropoiesis and subsequent lethality to the hepatocytes being sensitized to 
oxidative stress as a result of the TCF11 deficiency (62). This is further evidence that 
TCF11 could be an essential factor in the redox balance in cells. 
 
Notably, an increased mortality due to over-expression of TCF11 has been detected in 
both stably transfected HeLa cells and transiently transfected COS-1 cells (personal 
communication, C. Husberg). These observations present the possibility that TCF11 
may be involved in the regulation of cell death.  
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1.3 Regulation of regulatory transcription factors 
 
The level in which a target gene is transcribed is dependent both on the concentration 
and the activity of the regulatory transcription factors. The regulation of the 
transcription factors themselves is therefore a key control point of the target gene 
production. Several of the numerous mechanisms involved in the regulation of 
transcription factors are given below, with emphasis on the mechanisms affecting 
TCF11. 
 
1.3.1 Regulation of the expression level 
 
Regulation at the transcriptional level is the primary means by which the 
concentration of proteins is controlled. This allows the expression of transcription 
factors to be restricted to specific cells and tissues. An example of this is the 
regulatory transcription factor p45 NF-E2, which have been shown to be restricted to 
hematopoietic tissues and cell-lines (63). Another way in which the production of 
many cell-type specific transcription factors is regulated is by means of auto-
regulation. This is a mechanism where factors, like Pit-1, are involved in their own 
transcriptional activation (64). TCF11, however, is a ubiquitously expressed protein 
and is not likely to be regulated by these mechanisms (25). 
 
A different process in which the expressional level of a regulatory transcription factor 
is regulated is through alternative splicing of mRNA. Splicing is the process of 
excising the numerous non-coding introns from the coding exons in the pre-mRNAs 
(primary transcript), thereby creating functional mRNA. By splicing the exons in 
varied combinations, diverse mRNAs, and thereby proteins with different functions 
and activities can be produced from the same gene. One example is the CREM gene, 
which has been shown to generate both activators and repressors through alternative 
splicing (65). Alternative splicing can produce several isoforms of TCF11, one being 
the Nrf1 (Section 1.2.2.5). The activity level measurements of this isoform have given 
ambiguous results, however, displaying both an unchanged level of activity (49), and 
a reduced level of activity (personal communication, E. Bjørgo) when compared to 
TCF11. 
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A different manner in which various isoforms of the same transcription factor can be 
obtained is through initiation of translation from different start codons within the 
mRNA-transcript. While the optimal start codon sequence is called the Kozak-
sequence (ACCAUGG), translation can also start from non-optimal sequences (66). 
The mRNA transcript of the transcription factor C/EBP gene contains both an early 
non-optimal and an internal perfect Kozak-sequence. In this case, the cell-regulated 
initiation from the distinct start sequences results in two protein isoforms with 
different transcription activation potentials, one being an activator (full-length form), 
while the other is a repressor (67). This mechanism has been shown to produce 
isoforms of TCF11, one being the LCR-F1 (Section 1.2.2.5). As mentioned earlier, 
this isoform has displayed a lack of activity on its own, and its presence has also been 
seen to reduce the transactivating ability of full-length TCF11 (56). 
 
The stability, or rate of degradation, of an mRNA molecule is also a factor regulating 
the expression of transcription factors. Genes that are expressed in high levels, such as 
-globin (68), requires mRNA’s that are highly stable. This allows the protein 
translation to continue long after transcription is repressed. In contrast, numerous 
genes that code for transcription factors, such as c-Fos and c-Jun, have rapidly 
changing production levels and are therefore dependent on having mRNAs that are 
unstable and with short half-lives (69). The stability of mRNA is dependent on 
specific structural components, some of which include the 5’-cap structure and the 3’-
polyadenylate (poly(A)) tail. These are key components in the major degradation 
pathway, which starts by the shortening of the poly(A) tail through exonuclease 
activity, followed by the removal of  the 5’-cap, and the eventual bidirectional 
degradation of the mRNA (68). The rate of mRNA degradation can therefore be 
affected by the stability of these components. As an example, the stability of the 
HNF-1 protein is affected by variation in length of the poly(A) tail due to alternative 
splicing (70). Specific sequences in the molecule may also contribute to mRNA 
instability. One example is the AUUUA-sequence that appears to make mRNA 
unstable when occurring in multiple copies in the 3’ untranslated region of the 
molecule (69,71). Studies have revealed a slightly larger isoform of TCF11 containing 
both a longer poly(A) tail and the presence of additional AU-rich sequences. 
Interestingly, the longer form appeared to be more abundant in all tissues examined 
(25). 
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1.3.2 Regulation of activation 
 
Once the transcription factor has been translated from mRNA, the regulation is 
accomplished by controlling the activity level of the factor, thereby affecting the 
expression of target genes. Several of these regulating mechanisms are presented 
below. 
 
1.3.2.1 Regulation of DNA-binding and transactivation  
 
Post-translational modification of proteins is a way of achieving this kind of 
regulation. Phosphorylation and dephosphorylation of proteins are common 
modifications that either negatively or positively regulate transcription factor activity. 
In the case of the transcription regulator termed Snail, phosphorylation caused a 
reduction in the ability to activate transcription, while the DNA-binding ability was 
left intact (72). Phosphorylation has the opposite effect on CREB and increases the 
protein’s transactivating ability by allowing for the interaction with co-factors 
CBP/p300 (73). The role of phosphorylation in the regulation of TCF11 has not been 
studied extensively. However, the multiple phosphorylation-sites observed in the 
serine-rich domain have been suggested to play an important role in regulating the 
activity of TCF11 (49). 
 
The activity of a transcription factor can also be regulated through interactions with 
other proteins. Such interactions may modulate the DNA binding specificity of a 
protein, in addition to altering its potential as an activator or repressor of transcription. 
The bZIP-superfamily (Section 1.2.1) is an example of proteins that utilize this type 
of regulation. These proteins bind by means of their leucine zipper, forming 
homodimers and/or heterodimers with varying effect on the activity. As mentioned 
earlier, the heterodimeric complex consisting of p45 NF-E2 (Section 1.2.2.1) and a 
small Maf protein results in a transcriptional activating dimer, while homodimers of 
the small Maf proteins themselves are unable to activate transcription (74,75). TCF11 
have also been observed to form dimers with the small Maf proteins (53). However, 
most of the heterodimers tested have displayed a repressed activity when compared to 
that of the TCF11 homodimer. 
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1.3.2.2 Regulation of intracellular localization 
 
Restricted intracellular localization is another means of regulating the activity level of 
a regulatory transcription factor. Since the target DNA is located in the nucleus, 
restricting the protein’s nucleocytoplasmic transportation can be an efficient way to 
control its activity. The nucleocytoplasmic transport occurs through the nuclear pore 
complexes (NPC), which penetrate the nuclear envelope surrounding the nucleus (76). 
The NPCs allow slow passive diffusion of proteins smaller than ~60 kDa, while larger 
molecules, like transcription factors, are dependent on active transportation (77). 
Active transportation in either direction across the nuclear envelope involves 
sequential steps. These include: recognition of the protein’s transport signal by a 
transport receptor, docking of the protein/receptor complex at the NPC, translocation 
through the NPC and release of the transported protein (77,78). There are two 
different types of translocation signals depending on the direction of transport. Two 
well-studied examples are the previously mentioned NLS, which is essential for 
nuclear import (79), and NES, required for nuclear export (80,81).  
 
One way to control the intracellular localization, and consequently the activating 
ability of a transcription factor, is therefore to regulate its affinity to the transport 
receptor by masking or unmasking the transport signal. This can be achieved either by 
phosphorylation or by association with accessory proteins (82). In the case of Smad4, 
phosphorylation caused the masking of NES and unmasking of NLS, resulting in 
nuclear localization and a subsequent increase in activation (83). However, 
phosphorylation may also decrease the activity by instigating cytoplasmic 
localization, either due to the unmasking of NES, as was the case for MK2 (84), or the 
masking of NLS, as seen for AFX. (85). The NF-B, on the other hand, displayed 
cytoplasmic localization upon forming a complex with IB (86). The IB is an 
inhibitory protein that masks the NLS signal in the NF-B protein, thereby rendering 
the protein inactive in the cytoplasm. 
Some proteins also use nuclear shuttling to regulate their activity. These proteins 
continuously move between the cytoplasm and the nucleus, and their steady-state 
localization reflects their relative rates of nuclear import and export. An example of 
this is the yeast AP-1 like (Yap1) transcription factor. The steady state of this protein 
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is cytoplasmic, but shows nuclear accumulation when exposed to oxidative stress. 
This response is due to inhibition of the nuclear export pathway (87).  
 
Unlike TCF11, Nrf1 lacks the functional NES signal and appears to be restricted to 
the nucleus. Interestingly, however, the nuclear accumulation of Nrf1 does not give an 
elevated activity compared to TCF11, as mentioned earlier. 
 
1.3.2.3 Regulation of protein stability 
 
Another means to terminate the activity of a transcription factor is by regulating the 
rate of protein degradation. By altering the protein stability, the transcription factor’s 
longevity varies, thereby changing the overall activity of the protein. Examples of 
proteins regulated in this manner are the transcription regulators p53 and GCN4p, 
which are degraded by the well-documented ubiquitin-dependent proteolysis pathway 
(88,89). By conjugating with ubiquitin molecules, the proteins are tagged for the 
subsequent destruction by the proteasome (88). The role of the degradation pathway 
in regulating the activity of TCF11 is unknown. 
The activity of a transcription factor will often consist of a compilation of the 
regulating mechanisms mentioned. In the case of transcription factor Pho4, multiple 
phosphorylation sites provide numerous layers of regulation that modulate its activity 
(90). For instance, both the nuclear export and import have seen to be mediated by 
phosphorylation. In addition, phosphorylation allows for the dimerization of Pho4 
with the Pho2 transcription factor, needed for the transcriptional activation of the 
target gene PHO5. 
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1.4 Aims of the study 
 
The transactivating ability and intracellular location of TCF11/Nrf1 have so far been 
studied in cell-lines by means of a high expression vector system. Due to the detected 
increase in cell mortality as a result of over-expression of TCF11/Nrf1, the aim of this 
study was to construct vectors that expressed TCF11 and Nrf1 at lower levels. 
Subsequently, the high and low expressing vectors would be compared with respect to 
the transactivating ability and intracellular localization of TCF11 and Nrf1.  
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2 Materials and Methods 
 
Buffers and standard solutions were made according to Sambrook, et al (91) unless provided 
in the kits used. 
 
2.1 Biological material 
 
2.1.1 Growth of E.coli 
 
Escherichea coli (E.coli) XL1-blue Mrf was grown in LB media (1% Trypton, 5.6 mM 
Glucose, 171 mM NaCl, 0.5% Yeast extract) containing 50 µg/ml ampicillin. Incubations 
were done in a Controlled Environment incubator shaker (New Brunswick Scientific) at 37°C 
over night (ON). 
 
For screening purposes, the E.coli bacteria were plated on LB agar (LB, 1.25% Agar No.1) 
containing 50 µg/ml ampicillin, and incubated ON in a Termaks incubator. Other media used 
were SOB (2% Trypton, 0.5% Yeast extract, 9 mM NaCl, 2.5 mM KCl, 10 mM MgCl2) and 
SOC (2% Trypton, 0.5% Yeast extract, 20 mM Glucose, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2). 
 
2.1.2 Growth of COS-1 
 
COS-1 cells were cultured in Dulbecco’s Modified Eagle’s Medium with 1g/l glucose 
(DMEM, Life Technologies) added 10 % Foetal Calf Serum, 2 mM L-Glutamine, and 50 
U/ml penicillin/Streptomycin. The incubations were done in a water-jacketed incubator 
(Forma Scientific) at 37°C and 5% CO2. 
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2.1.3 Plasmid constructs 
 
A list of pre-made plasmid constructs used in this study is displayed in table 2-1. 
 
Table 2-1Pre-made plasmids used in this study 
Name of plasmid Description  Source 
pcDNA3 Vector containing the strong promoter human 
cytomegalovirus immediate-early (CMV), and is 
designed for high-level stable and transient 
expression in mammalian cells. The vector contains 
the ampicillin resistance gene as a selection marker. 
 Invitrogen 
pcNrf1 
(pcTCF11 ∆242-271) 
The gene for full length TCF11, with the amino 
acid residues 242-271 excised, cloned into the 
pcDNA3 vector (Invitrogen). 
 Constructed by  
Dr. Elisa Bjørgo (50). 
pcTCF11 
 
The gene for full length TCF11 cloned into the 
pcDNA3 vector (Invitrogen). 
 Constructed by  
Dr. Cathrine Husberg (56). 
3.2PBGDLuc A pGL3-Enhancer Vector (Promega) containing the 
luciferase gene under the control of a part of the 
porphobilinogen deaminase (PBGD) gene 
promotor. The promoter region contains a single 
NF-E2 site which can be activated by TCF11. The 
reporter vector also contains the gene for ampicillin 
resistance as a selection marker.  
 Constructed by  
Dr. Paula Murphy (55). 
3.2PBGDLuc Mut. 1 3.2PBGDLuc vector containing a one-base 
mutation in the NF-E2 binding site. This mutation 
is located outside the AP-1 binding site. 
 Constructed by  
Dr. Paula Murphy (55). 
3.2PBGDLuc Mut. 2 3.2PBGDLuc vector containing a four-base 
mutation in the NF-E2 binding site. This mutation 
is located inside the AP-1 binding site. 
 Constructed by  
Dr. Paula Murphy (55). 
pRL-TK Vector containing the weak promoter herpes 
simplex virus thymidine kinase (HSV-TK), with the 
ampicillin resistance gene as a selection marker. 
 Promega 
puC19  Vector used for testing competent cells. The vector 
contains the gene for ampicillin resistance as a 
selection marker 
 Stratagene 
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2.2 Cloning and DNA techniques 
 
2.2.1 Isolation of plasmid-DNA from E.coli 
 
Plasmid DNA isolation from ON LB cultures of E.coli was done by alkaline lysis of the 
bacterial cell wall in the presence of SDS detergent. This treatment opens the cell wall, 
allowing for denaturing of the genomic DNA and proteins, while releasing the plasmid DNA. 
The plasmid DNA was precipitated in isopropanol and finally dissolved in MilliQ-purified 
water (MQ-water). 
 
Two types of DNA isolations were used depending on the purpose, amount, and purity of the 
DNA needed. For the isolation of small quantities of plasmid DNA used for screening 
purposes, the minipreparation protocol described in Sambrook, et al (91) was followed. For 
the isolation of larger quantities of purified DNA, the Plasmid Midi Kit (Qiagen) was used, as 
described by the manufacturer. A protocol deviation was the replacing of the supplied TE-
buffer with MQ-water. The midiprepared plasmid DNA was quantified (Section 2.2.3). 
 
2.2.2 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was used to separate, identify and purify DNA molecules. The 
molecules are separated by means of an electrical field, where the rate of movement is 
dependent on the voltage applied, the ionic strength of the buffer used, and the concentration 
of the agarose gel. The intercalating agent ethidium bromide (EtBr) was added to the gel 
(0.5µg/ml) to allow for UV visualization by means of a Saveen TFP-35M (Vilber Lourmat) 
apparatus. The Power Pac300 (BioRad) was used as the power source. Two types of agarose 
gel electrophoresis were used, analytical and preparative. 
 
Analytical agarose gel electrophoresis was used to quantify DNA and to determine the size of 
DNA molecules. The gels ranged from 0.8-2.0% agarose (Sigma) using 1xTBE as a running 
buffer. 
 
Preparative Agarose Gel Electrophoresis was used to isolate purified DNA from 1.0% agarose 
gels (SeaKem GTG agarose [FMC BioProducts]). The running buffer used with this
Section 2                                                                                                     Materials & Methods 
 
21 
agarose was 1xTAE. DNA fragments to be purified were extracted from agarose according to 
the QIAEX II Gel Extraction Kit (QIAGEN) protocol. 
 
2.2.3 Quantification of DNA 
 
DNA was quantified primarily by means of the GeneQuant (Pharmacia Biotech) 
spectrophotometer. The concentration of DNA in a sample was determined by measuring the 
optical density (OD) at 260nm, where a value of 1 corresponds to a concentration of 50 µg/ml 
for dsDNA and 30 µg/ml for ssDNA.  
 
In addition, some DNA concentrations were determined through analytical agarose gel 
electrophoresis (Section 2.2.2). Here, quantification was done by comparing DNA fragment 
intensity to that of known concentrations of a DNA standard (Lambda DNA/Hind III 
[Promega]). 
 
2.2.4 Digestion of DNA with restriction enzymes 
 
Digestion of DNA was performed to do restriction mapping and for constructing plasmids. 
The restriction enzymes, with their accompanying buffers (NEB), were used as recommended 
by the manufacturer. All reactions were incubated in a PTC-100 (MJ Research, Inc) PCR 
apparatus, while heat inactivation was completed in a BBD2 (Grant-Boekel) heating block. 
 
2.2.5 Ligation of DNA fragments 
 
Ligation was performed using T4 DNA ligase in ligation buffer (NEB) as recommended by 
the manufacturer. All reactions were incubated in a PTC-100 (MJ Research, Inc) PCR 
apparatus ON at 16˚C. 
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2.2.6 Blunting of DNA 
 
Klenow DNA Polymerase (NEB) with added dNTPs (Amersham Pharmacia Biotech) was 
used to blunt DNA fragments with sticky ends by means of its 5’→3’ polymerase activity. 
The reaction was set up as recommended by the manufacturer. A PTC-100 (MJ Research, 
Inc) PCR apparatus was used for the 15 minute incubation at 25˚C, while a BBD2 (Grant-
Boekel) heating block was used for the 10 minute heat inactivation at 75˚C. 
 
2.2.7 Making electrocompetent cells 
 
In order to make E.coli competent, or susceptical to the uptake of foreign DNA, the bacterial 
outer and inner cell membrane will have to be made penetrable. This was achieved by 
exposing E.coli to a combination of heat shocking and DMSO, as described in Sambrook et 
al. (91). The cells were frozen in liquid nitrogen and kept at -80°C.  
 
2.2.8 Transformation of E.coli by electroporation 
 
Electrocompetent E.coli (Section 2.2.7) were transformed using electroporation. By means of 
electric pulses, generated by the Gene Pulser/Pulse Controller (BioRad) apparatus, transient 
pores are created in the membranes of the E.coli, allowing for DNA uptake. 
 
1 ng of plasmid DNA was added to 40 µl of thawed electrocompetent cells and incubated for 
1 minute on ice. The suspension was transferred to a cold cuvette (BioRad) and electroporated 
with a pulse of 2.5 kV, resistance of 400Ω, and a capacitance of 25 µF. SOC-media at 37°C 
was immediately added, and the suspension was incubated on a shaker at 37°C for 1 hour. 
The cell suspension was plated on LB agar plates containing 50 mg/ml ampicillin and 
incubated at 37°C ON in order to screen for transformed cells. The transformation efficiency 
of the electrocompetent cells was determined by transforming the competent cells with a 
pUC19 control plasmid. By plating a dilution series of the transformed suspension, the 
efficiency was calculated as the number of colonies per µg of pUC19. 
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2.2.9 Screening for transformants 
 
Screening for transformants was done in two steps. Plasmid DNA was miniprepared from ON 
cultures of transformed bacterial colonies, followed by a restriction analysis to screen for 
desired clones. The plasmid DNA was also sequenced (Section 2.2.10) to further verify the 
obtained clone. 
 
2.2.10 Automatic sequencing of DNA 
 
The automatic sequencing was completed by Henning A. Johansen at the Biotechnology 
centre of Oslo. The sequencing was done by using an A.L.F. DNA Sequencer (Pharmacia 
Biotech). The sequencing primer (5’ GAAACGGAGCAGGGATTCGG 3’) was synthesized 
by Dr. Eshrat Babie at the DNA synthesis laboratory in the Biotechnology centre of Oslo. 
 
2.3 Cell Techniques 
 
2.3.1 Transfection 
 
Transfection is the process in which foreign DNA is taken up by eukaryotic cells and is 
essential in studying gene function and regulation. The uptake of DNA is temporary in a 
transient transfection, while in a stable transfection the DNA is incorporated into the cell’s 
genome. In this study, transient transfection was done by using FuGENE (Roche Molecular 
Biochemicals) as a transfection reagent. FuGENE consists of a lipid mixture that encapsulates 
the DNA and transports it into the cell through cell membrane fusion. However, the details of 
this mechanism are not known.  
 
COS-1 cells (70-80% confluent) were split 18-20 hours before transfection, allowing the cells 
to reach 50-60% confluence. The cells were transfected with 0.8-2.0 µg DNA using a 
FuGENE to DNA ratio of 3 µl :1 µg. The manufacturer’s protocol was used. 
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2.3.2 Luciferase-assay 
 
The luciferase-assay was used to study TCF11’s ability to activate transcription. The assay is 
based on the ability of TCF11 to bind to its respective binding sites and activate transcription 
of the luciferase gene located in the PBGD reporter plasmid. Luciferase, in turn, reacts with 
and breaks down added luciferin, causing the emition of a yellow-green light (Fig. 2-1). This 
light is detected and quantized by a luminometer. The light intensity can therefore be used to 
correlate TCF11’s ability to activate transcription. 
 
 
Figure 2-1The catalyzed reaction of the luciferase enzyme. The enzyme reacts with luciferin and as a result, 
light (h) is emitted. 
 
2.3.2.1 Luciferase activity measurement 
 
Three parallels of each DNA construct, along with a standard amount of 0.2µg of the PBGD 
reporter plasmid, were transfected into COS-1 cells and incubated for 48 hours before 
harvesting. All samples were kept on ice at all times. 
 
Growth media was removed and the cells were washed twice in PBS. 150 µl of luciferase-
lysis buffer (50 mM Tris-MES [pH 7.8], 1mM DTT, 0.1% Triton X-100), was added and incubated 
for 5 minutes. The cells were harvested and centrifuged at 13000 rpm for 5 minutes at 4°C 
(Biofuge fresco, Heraeus instruments). 5, 10 and 20 µl of the supernatant was mixed with 
195, 190 and 180 µl luciferase cocktail (10 mM Mg(OAc)2, 50mM Tris-MES [pH 7.8], 2mM 
ATP) respectively, and the luciferase activity was measured using a MicroLumat Plus 
luminometer (EG&G Berthold). 
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2.3.2.2 Normalization of the luciferase activity 
 
The relative protein content in the cell extracts was used to normalize the luciferase activity 
measurements. A Protein assay kit (BioRad) was used for this purpose. 
 
The concentrated Bio-Rad protein assay substrate was diluted four times with MQ-water. 2 ml 
of the diluted substrate and 5-10 µl of each sample was added to disposable cuvettes 
(Rankell), followed by a 5-minute incubation. The samples’ absorbance of light at 595 nm 
were measured by using the U-1500 Spectrophotometer (Hitatchi Instruments). The blank 
consisted of substrate lacking sample. 
 
2.3.3 Western Analysis 
 
Western analysis was used to detect and quantify specific proteins in transfected cells, and 
involves SDS-PAGE and Western blotting.  
 
2.3.3.1 Harvesting of cells 
 
Two parallels of each DNA construct were transfected into COS-1 cells and incubated for 24-
30 hours before harvesting. 
 
Growth media was removed and the cells were washed twice with PBS. 75 µl of 2 x SDS gel 
loading buffer (100mM Tris-HCl [pH 6.8], 200mM DTT, 4% SDS, 0.1% Bromphenol blue, 
20% Glycerol) heated to 85°C was added to the cells. The cells were harvested, denatured at 
100°C for 10 minutes and filtered through a 25GA needle (Becton Dickinson). Following a 
centrifugation (Biofuge fresco, Heraeus instruments) at 13000 rpm for 5 minutes, the 
supernatant was applied to an SDS-PAGE-gel. 
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2.3.3.2 SDS-polyacrylamide gel electrophoresis 
 
SDS-PAGE was used in the size separation of proteins from lysed cells. The negatively 
charged detergent sodium dodecyl sulfate (SDS) binds and denatures proteins, thus masking 
the charge of the proteins. The proteins can therefore be separated based solely on size and 
not charge. A concentrating gel (”stacking gel”) was applied on top of the resolving gel in 
order to concentrate the proteins. In this work, the electrophoresis equipment Mini Protean II 
(BioRad) and Power Pac 300 (BioRad) were used. 
 
A 10% resolving gel was made (1.7 ml 29% Acrylamide/1% Bisacrylamide, 1.3 ml 1.5M Tris 
[pH 8.8], 0.05 ml 10% SDS, 1.9 ml MQ-water, 25 µl 10% APS, 2.5 µl TEMED) and poured 
between the glass plates, allowing for a 30 minute polymerization. Subsequently, a 5% 
stacking gel solution (0.33 ml 29% Acrylamide/1% Bisacrylamide, 0.25 ml 1.5M Tris [pH 
6.8], 0.02 10% SDS, 1.4 ml MQ-water, 10 µl 10% APS, 2 µl TEMED) was poured onto the 
resolving gel and the comb was inserted. 
 
After polymerization, the comb was removed and the wells were washed with MQ-water to 
remove unpolymerized acrylamide. The gel was placed in the electrophoresis apparatus and 
filled with 1x SDS-electrophoresis buffer (125 mM Tris, 1 M Glycine, 0.5% SDS). The 
protein samples were thawed, denatured at 95°C for 5 minutes, and loaded on the gel in 15-20 
µl aliquots. 10 µl of the Prestained Broad Range marker (BioRad) was used as a size marker. 
The samples were run at 100V through the stacking gel and 120-150V through the resolving 
gel (~2 hours). 
 
2.3.3.3 Western blotting 
 
Western blotting was used to detect a particular protein(s) in a gel using antibodies. Proteins 
separated on an SDS-PAGE were transferred to a PVDF membrane (Immobilon-P, Millipore) 
by means of an electric current. Following the transfer, the membrane was incubated with a 
primary antibody that is binding-specific for the desired protein. By incubating the membrane 
with an alkaline phosphatase (AP)-conjugated secondary antibody that has a high binding 
specificity for the primary antibody, the proteins can be visualized by adding AP 
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dephosphorylating ECF Substrate (Bio-Rad), which produces a fluorescent product. The 
Trans-Blot Cell (BioRad) blotting apparatus and the Microcomputer Electrophoresis Power 
Supply (CONSORT) were used. 
 
A PVDF membrane was activated in methanol for 1 minute and washed with ice-cold blotting 
buffer (25 mM Tris, 200mM Glycine, 20% Methanol). The transfer unit was assembled (Fig. 
2-2) and placed in the blotting chamber, which contained blotting buffer and a cooling 
element, with the membrane towards the anode and the SDS-gel towards the cathode. The 
blotting proceeded for 2 hours at 85V, replacing the cooling element after 1 hour. 
Subsequently, the membrane was blocked in blocking solution (5% Dry milk, 1% Glycine, in 
TBST (165 mM NaCl, 10 mM Tris [pH 8.0], 0.1% Tween-20)) for 1 hour at room 
temperature (RT), washed three times in TBST at 4°C, followed by primary antibody 
incubation (1:1000 of rabbit anti-Nrf1 (C-19) [Santa Cruz Biotechnology] in TBST and 5% 
dry milk) ON at 4°C. After completed incubation, the membrane was washed three times in 
TBST, followed by a 2 hour incubation with the secondary antibody (1:2000 Donkey anti-
rabbit AP conjugate [Santa Cruz Biotechnology] in TBST and 5% dry milk) at 4°C. The 
membrane was washed three times in TBST and dried.  
 
The membrane was placed in enhanced chemifluorescence (ECF)-solution and incubated for 
30 seconds, before photographing it by using a Storm Bluescreen Storm 860 Scanner 
(Molecular Dynamics). The migration lengths of the marker proteins, measured from the start 
of the resolving gel, were plotted on the x-axis of a graph paper. The log of the marker protein 
sizes were plotted on the y-axis, and a standard curve was calculated. The unknown molecular 
weights were then determined. Subsequently, the quantities of the different protein products 
were estimated. The fluorescing intensity is directly related to the amount of protein present. 
Therefore, the protein quantity was estimated by compare the intensity of the desired bands to 
that of the background bands by using the ImageQuant 5.2 software (Amersham Biosciences).  
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Figure 2-2 Western blotting transfer-unit assembly. 
 
2.3.4 Immunocytochemistry 
 
Immunocytochemistry was used to study the intracellular localization of TCF11. The proteins 
were visualized through immunofluorescence, using a fluorescein isothiocyanate (FITC) 
coupled antibody specific for a TCF11/Nrf1-recognizing antibody. The UV-excitable Hoechst 
33342 nuclei stain was added to simplify the localization of the cells, and the images were 
acquired by means of epifluorescence and confocal microscopy. 
 
2.3.4.1 Cell fixation and labelling 
 
Cells growing on 10 mm2 cover slips were transfected, followed by 24-30 hours of 
incubation. 
 
The cover slips with the adhered transfected cells were washed twice for 2 minutes in PBS. 
The cells were then fixed in 200 µl 4% paraformaldehyde for 7 minute at RT, followed by 
two washes in PBS and three washes for 5 minutes in washing buffer (PBS, 1% BSA, 0.1% 
NP40, 0.001% NaAzide). The cells were then labelled with the primary antibody (1:1000 
rabbit -Nrf1 (C-19) [Santa Cruz Biotechnology] or 1:10000 rabbit -TCF11 (53) in washing 
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buffer) ON at 4°C. Following three washes in washing buffer, the cells were labelled with the 
secondary antibody (1:330 Swine-anti rabbit FITC conjugate [DAKO] in washing buffer) for 
60 minutes at RT, and then washed twice in washing buffer, once in PBS and finally rinsed 
off in MQ-water. The cover slips were mounted with the cell-side down in 5 µl of mounting 
solution (10% MOWOIL [Calbiochem]) containing 1 µg/ml Hoechst 33342 (Molecular 
Probes) for chromosome staining. 
 
2.3.4.2 Epifluorescence microscopy 
 
Images were acquired by means of a Leitz DM RXE microscope stand (Leica) equipped with 
a 40x/0.70 oil immersion objective and an F-view digital camera (Soft Imaging System). A 
UV-filter was used for the detection of hoechst, while a blue filter was used to detect FITC. 
Images were acquired and processed using the Analysis software (Soft Imaging System). 
 
2.3.4.3 Digital Confocal Laser-Scanning Microscopy 
 
Images were acquired with a Leica upright microscope stand equipped with a 100x/1.25 oil 
immersion objective, a TCS-SP digital scanning head (Leica) and a He/Ne/Ar laser lined at 
488 nm for FITC excitation. To obtain a specific signal, the emition light was filtered through 
a 514-540 nm band pass. The z-position of the laser was adjusted to the nucleic centre of the 
cell, and the sample was scanned using the Leica confocal software. 
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3 Results 
 
Preliminary studies in our group have indicated that high expression of TCF11 has a toxic 
effect on mammalian cells in culture. In addition, over-expression makes detailed cell-
localization of the proteins difficult. To circumvent this problem, TCF11 could be put under 
the control of a weak promoter, either by inserting TCF11 into a vector containing a weak 
promoter, or by replacing a strong promoter with a weak promoter in an existing TCF11 
construct. Both methods were attempted. In addition, low expressing plasmids containing 
Nrf1, a naturally occurring isoform of TCF11 lacking 30 aa’s, was also constructed. 
 
3.1 pRL-TK based TCF11/Nrf1 expressing plasmids 
 
The initial idea in constructing low TCF11 and Nrf1 expression vectors was by cloning 
TCF11/Nrf1 into a pRL-TK vector. This vector contains the herpes simplex virus thymidine 
kinase (HSV-TK) promoter, which provides low to moderate levels of expression. By 
excising the Renilla luciferase (Rluc) gene within the pRL-TK vector and inserting the TCF11 
or Nrf1 genes, the resulting plasmids should express low levels of TCF11 or Nrf1.  
 
3.1.1 Construction of pTK, pTK-TCF11 and pTK-Nrf1 
 
The pRL-TK, pcTCF11 and pcNrf1 plasmids were transformed into E.coli cells (section 
2.2.9) and plasmid DNA was isolated in midipreps from ON cultures (section 2.2.1). The 
plasmids were used to make the pTK-based constructs displayed in table 3-1. 
 
Table 3-1 pTK-based constructs containing TCF11/Nrf1 
Name Description 
pTK pRL-TK vector with the Rluc-gene excised. 
pTK-TCF11 pTK with TCF11 inserted. 
pTK-Nrf1 pTK with Nrf1 inserted. 
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The pTK construct was constructed by digesting the pRL-TK vector with Xba I and Nru I 
restriction enzymes (section 2.2.4), thus removing the Rluc-gene from the vector and leaving 
compatible sticky ends. The opened vector was isolated and purified using preparative 
agarose gel separation (section 2.2.2), followed by re-ligation of the vector (section 2.2.6). 
Following transformation, twenty colonies were mini-prepared and analyzed by restriction 
analysis with Hind III. The restriction analysis gel of one positive clone of each plasmid is 
shown in figure 3-1. The cleaved pRL-TK vector displayed a ~4kb fragment (Fig. 3-1, lane 
1), while the cleaved pTK vector revealed ~3.1kb fragment (Fig. 3-1, lane 2). Since the Rluc 
gene is 0.9kb in size, the size difference between the two vectors demonstrates that the 
removal of Rluc was successful. 
 
 
Figure 3-1Restriction analysis of pRL-TK and pTK.  Lane 1 contains the pRL-TK vector digested with   Hind 
III, while lane 2 contains pTK digested with Hind III. 
 
The pTK plasmid was midi-prepared (section 2.2.1). 
 
The construction of the pTK-TCF11 and pTK-Nrf1 plasmids was completed in several steps. 
The TCF11 and Nrf1 genes were isolated from the pcTCF11 and pcNrf1 plasmids through 
enzyme digestion and ligated with the pTK construct, as shown in figure 3-2. 
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Figure 3-2 Construction of low expression plasmids by cloning TCF11/Nrf1 into pRL-TK vector : The 
TCF11/Nrf1 was isolated from the pcTCF11/pcNrf1 plasmids through Eco RI digestion and blunting with 
Klenow (section 2.2.7) , followed by digestion with Xba I. The Rluc gene was excised from the pRL-TK vector 
through Nhe I digestion, blunting with Klenow, followed by digestion with Xba I. The opened pRL-TK vector 
and isolated TCF11/Nrf1 genes was ligated to form the pTK-TCF11/pTK-Nrf1 plasmids. The pTK vector was 
constructed by excising the Rluc gene from the pRL-TK vector through Xba I and Nru I digestion, followed by 
re-ligation of the vector (not shown). The constructs were transiently transfected into COS-1 cells for further 
studies. 
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The ligated products were transformed and twenty colonies were mini-prepared and examined 
through restriction analysis with Xba I and Psh AI cleavage. The restriction analysis gel of 
one positive clone of each plasmid is shown in figure 3-3. Two fragments with sizes ~4kb and 
~2.3kb were seen for the digested pTK-Nrf1 plasmid (Fig. 3-3, lane 4), two fragments with 
sizes ~4kb and ~2.4kb for the digested pTK-TCF11 plasmid (Fig. 3-3, lane 6) and one ~4kb 
fragment for the digested pRL-TK plasmid (Fig. 3-3, lane 2). This is compliant with the 
expected results since all three plasmids have one Xba I restriction site, while the Psh AI 
cleaves strictly in the TCF11 and Nrf1 containing plasmids, thus verifying that the cloning 
was successful.  
 
 
 
Figure 3-3 Restriction analysis of pRL-TK, pTK-TCF11 and pTK-Nrf1 plasmids.  The pRL-TK (lane 2), 
pTK-Nrf1 (lane 4) and pTK-TCF11 (lane 6) constructs were digested with Xba I and Psh AI restriction enzymes. 
Lanes 1, 3 and 5 contain undigested plasmids. The plasmid maps show the restriction sites for both enzymes.   
 
The constructs were midi-prepared and the identity was further confirmed by DNA-
sequencing (section 2.2.11).  
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3.1.2 Transactivation assay of pTK-TCF11 and pTK-Nrf1 
 
The transactivating ability of the pTK-based TCF11/Nrf1-containing constructs was analyzed 
by means of luciferase activity assays. The constructs were transiently co-transfected into 
COS-1 cells (section 2.3.1) with the 3.2PBGDLuc reporter plasmid, and the luciferase activity 
was measured (section 2.3.2) (Fig. 3-4). The experiment showed that the pTK-TCF11 plasmid 
(Fig. 3-4, bar 2), and the pTK-Nrf1 plasmid (Fig. 3-4, bar 3), gave a 0.6 and 0.3 fold reduction 
in activity, respectively, when compared to the empty pTK vector (Fig. 3-4, bar 1). 
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Figure 3-4 Luciferase induction by pTK-constructs transiently transfected in COS-1 cells: 0.2µg of the 
3.2PBGDLuc reporter was co-transfected with 0.8 µg of either empty pTK vector (bar 1), or one of the 
TCF11/Nrf1 constructs (bars 2 and 3). The luciferase activity was normalized (section 2.3.2.2) and is relative to 
the activity given with the empty vector. The induction shown is the average of 3 experiments, and the error 
bars reflect the standard deviation of the mean value.  
 
To investigate the ability of the pTK vector to activate luciferase transcription independently 
of the TCF11/Nrf1 proteins, COS-1 cells were transfected with an increasing amount of pTK 
to observe the variations in luciferase activity (Fig. 3-5). The co-transfection showed that an 
increase of transfected pTK induced an exponential increase of luciferase activity (Fig. 3-5, 
bars 1-3). The transfection of 2.0 µg of empty pTK vector (Fig. 3-5, bar 3) induced a 7.5 fold 
increase in luciferase activity compared to the activity of the empty pcDNA3 vector of equal 
transfectional amount (Fig. 3-5, bar 4). The 3.2PBGDLuc reporter by itself (Fig. 3-5, bar 5) 
did not induce any significant luciferase activity. 
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Figure 3-5 Luciferase induction in COS-1 cells transiently transfected with various amounts of pTK: 0.2 
µg of the 3.2PBGDLuc reporter was co-transfected with 0.8, 1.5, or 2.0 µg of the pTK vector (bars 1, 2 and 3), 
or 2.0 µg of the pcDNA3 vector (bar 4). In addition, transfection with the reporter alone was also included (bar 
5). The luciferase activity was normalized and is relative to the activity given with the 0.8 µg of pTK 
transfection (bar 1). The induction shown is the average of 3 experiments, and the error bars reflect the standard 
deviation of the mean value.  
 
To investigate if the activation of luciferase transcription is NF-E2 site dependent, the pTK-
TCF11 plasmid was transfected in the presence of normal 3.2PBGDLuc, but also with two 
reporters with mutations in the NF-E2 binding site. The first mutant reporter plasmid, 
3.2PBGDLuc Mut.1, contains a 1-base mutation outside the AP-1 binding site, while the 
second reporter plasmid, 3.2PBGDLuc Mut.2, contains a 4-base mutation located within the 
AP-1 binding site (Fig. 3-6).  
 
Co-transfection of the pTK-TCF11 plasmid and 3.2PBGDLuc Mut.1 reporter (Fig. 3-7, bar 3) 
showed an equivalent induction of luciferase activity to that of the pTK vector and 
3.2PBGDLuc reporter co-transfection (Fig. 3-7, bar 1), and therefore a higher activity 
compared to the pTK-TCF11 and 3.2PBGDLuc co-transfection. The pTK-TCF11 and 
3.2PBGDLuc Mut.2 co-transfection (Fig. 3-7, bar 4) showed a lower induction of luciferase 
activity compared to the pTK vector and 3.2PBGDLuc reporter co-transfection (Fig. 3-7, bar 
1), but gave a similar luciferase induction to that of the pTK-TCF11 and 3.2PBGDLuc co-
transfection (Fig. 3-7, bar 2).  
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Figure 3-6 NF-E2 core sequence of 3.2BGDLuc, 3.2PBGDLuc Mut.1 and 3.2PBGDLuc Mut.2 reporter 
plasmids.  The sequences represent the AP-1 binding site within the NF-E2 core binding site from the three 
reporter plasmids. The mutated regions are shown in red.  
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Figure 3-7 Luciferase induction in COS-1 cells transiently co-transfected with pTK-TCF11 and mutated 
reporter plasmids: 0.8 µg of pTK-TCF11 was co-transfected with 0.2µg of each the normal 3.2PBGDLuc 
reporter (bar 2) and the two mutated forms of the reporter plasmid, 3.2PBGDLuc Mut.1 and 3.2PBGDLuc Mut.2 
(bars 3 and 4, respectively). In addition, 0.8µg of the empty pTK vector was co-transfected with 0.2 µg of the 
3.2PBGDLuc reporter plasmid (bar 1).  The luciferase activity was normalized and is relative to the activity 
given with the pTK vector (bar 1). The induction shown is the average over a number (n) of experiments, and the 
error bars reflect the standard deviation of the mean value.  
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3.1.3 Investigation of possible transcription regulator motifs 
 
To investigate if the reporter induction was due to the presence of other potential 
transcriptional regulator binding sites, or motifs, the pcDNA3, pRL-TK and reporter vector 
were analyzed using the software program Motif. The search gave four different motifs that 
were located both in the pRL-TK and reporter vector, but absent in the pcDNA3 vector. These 
motifs bind the LyF-1, TCF3, HNF-3 and Brn-2 transcriptional regulators and were located 
at various sites in the vectors. Although none of the motifs were found in or near the PBGD 
promoter, the TCF3, HNF-3 and Brn-2 binding sites were all located within the luciferase 
gene.  
 
3.2 pcDNA3 and HSV-TK based TCF11/Nrf1 expressing plasmids 
 
Inserting the TCF11/Nrf1 genes into the pRL-TK vector created constructs that gave an 
unexpected result seeing that reporter induction occurred in the absence of TCF11 and Nrf1. 
Therefore, a different approach was devised. The weak promoter HSV-TK would now be 
inserted into the pre-made pcDNA3, pcTCF11 and pcNrf1 constructs, replacing the strong 
promoter CMV. This should transform the plasmids into lower expressing constructs. 
 
3.2.1 Construction of pcDNA3-TK, pcTCF11-TK and pcNrf1-TK 
 
To create the pcDNA3-based low expression constructs, the HSV-TK promoter was to be 
isolated from the pRL-TK vector. Two parallel approaches were attempted; the first was 
based on PCR amplification, whereas the second was based on enzymatic digestion. The latter 
proved to be the quicker method and was therefore chosen. 
 
The isolation of HSV-TK and excision of CMV promoter from the pcDNA3 constructs was 
completed in several steps of digestion and purification, following ligation of the fragments as 
displayed in figure 3-8. 
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Figure 3-8 Construction of low expression plasmids by cloning HSV-TK into pcDNA3 : The HSV-TK 
promoter was isolated from the pRL-TK vector through Bgl II digestion and blunting with Klenow, followed by 
digestion with Hind III. The CMV promoter was excised from the pcDNA3-vector through Nru I and Hind III 
digestion. The opened pcDNA3 vector and isolated HSV-TK promoter was ligated to form the pcDNA3-TK 
construct. The pcTCF11-TK and pcNrf1-TK plasmids were constructed in the same manner. The constructs were 
transiently transfected into COS-1 cells for further studied. 
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The obtained ligated products were transformed, and twenty colonies were mini-prepared and 
analyzed through two separate restriction analysis cleaving with Sac II and Sma I. The 
restriction analysis gel of one positive clone of each plasmid is presented in figure 3-9. The 
plasmids digested with Sac II displayed only one fragment as expected (Fig. 3-9, lanes 2, 5, 
8), since the enzyme only cleaves in the inserted HSV-TK promoter, thereby linearizing the 
plasmids. Digested pcDNA3-TK (Fig. 3-9, lane 2) showed a ~5.5kb fragment, while the 
digested pcTCF11-TK (Fig. 3-9, lane 5) and pcNrf1-TK (Fig. 3-9, lane 8) displayed fragments 
of sizes ~8.8kb and ~8.7kb, respectively, which were the expected sizes/fragments.  
 
The plasmids cleaved with the Sma I enzyme (Fig. 3-9, lanes 3, 6 and 9) showed multiple 
fragments. Digested pcDNA3-TK (Fig. 3-9, lane 3) showed two fragments of sizes ~1.7kb 
and ~3.8kb, digested pcTCF11-TK (Fig. 3-9, lane 6) showed three fragments of sizes ~1.4kb, 
~3.7kb and ~3.8kb, and the digested pcNrf1-TK (Fig. 3-9, lane 9) showed three fragments of 
sizes ~1.4kb, ~3.6kb and ~3.8kb. This was compliant with the expected result given that Sma 
I cleaves in the pcDNA3 vector, in the HSV-TK promoter, and in the TCF11/Nrf1 genes as 
displayed by the plasmid maps in figure 3-9. 
 
 
Figure 3-9  Restriction analysis of pcDNA3TK, pcTCF11-TK and pcNrf1-TK: Plasmids were cleaved with 
Sac II (lanes 2, 5 and 8) and Sma I (lanes 3, 6 and 9) restriction enzymes. Lanes 1, 4, and 7 contain undigested 
plasmids. The plasmid maps show the restriction sites for the Sma I enzyme. 
 
The pcDNA3-TK, pcTCF11-TK and pcNrf1-TK plasmids were midi-prepared. 
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3.2.2 Transactivation assay of pcTCF11-TK and pcNrf1-TK 
 
Prior to investigating the transactivating ability of the pcTCF11-TK and pcNrf1-TK 
constructs, the pcDNA3-TK vector was transfected in various amounts to see if it activated 
luciferase transcription in a similar manner to that of the pTK vector. The transfections did 
not reveal any significant variation in the induction of luciferase activity (Fig. 3-10).  
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Figure 3-10 Luciferase induction in COS-1 cells transiently transfected with pcDNA3-TK: 0.2µg of the 
3.2PBGDLuc reporter was co-transfected with 0.8, 1.5 or 2.0µg of the pcDNA3-TK construct (bars 1, 2 and 3, 
respectively). The luciferase activity was normalized and is relative to the activity given with the 0.8µg of 
pcDNA3-TK transfection (bar 1). The induction shown is the average of 3 experiments, and the error bars 
reflect the standard deviation of the mean value. 
 
To investigate the transactivating ability of the pcTCF11-TK/pcNrf1-TK constructs, the 
plasmids were analyzed by means of a luciferase assay (Fig. 3-11). High expression 
constructs were included in order to compare the luciferase activities and observe if the low 
expression constructs produced a reduced level of TCF11/Nrf1 compared to that of the high 
expression constructs.  
 
The high expression plasmid pcTCF11 (Fig. 3-11 A, bar 2) displayed a ten-fold increase in 
the induction of luciferase activity when compared to the induction of the low expression 
pcTCF11-TK plasmid (Fig. 3-11 B, bar 2). In addition, pcNrf1 (Fig. 3-11 A, bar 3) showed an 
average of 35% lower activity when compared to the activity of the pcTCF11 plasmid. The 
difference in activity between the pcTCF11-TK and the pcNrf1-TK plasmids (Fig. 3-11 B, 
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bars 2 and 3) could not be determined because the overall activities for the low expression 
plasmids were under the detection level of the assay. 
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Figure 3-11 Luciferase induction in COS-1 cells transiently transfected with high and low TCF11/Nrf1 
expressing plasmids: 0.2µg of 3.2PBGDLuc reporter was co-transfected with either (A) 0.8µg of the high 
expression TCF11/Nrf1 constructs (A, bars 2 and 3), including the empty pcDNA3 vector (A, bar 1) presented in 
red, or (B) 0.8 µg of the low expression TCF11/Nrf1constructs (B, bars 2 and 3), including the empty pcDNA3-
TK vector (B, bar 1) presented in green. Luciferase activity was normalized and is relative to the activity given 
with the respective empty vectors. The induction shown is the average of a number of experiments (n), and the 
error bars reflect the standard deviation of the mean value. 
 
To find the optimal transfection amount for the low expression plasmids, COS-1 cells were 
transfected with increasing amounts of expression DNA. The resulting luciferase assay (Fig. 
3-12) showed that cells transfected with 2.0µg of pcTCF11-TK plasmid (Fig. 3-12, bar 4) 
induced a luciferase activity that was approximately three and a half times that of the 
background (Fig. 3-12, bar 1). Also noticeable for the 2.0µg transfections was the activity of 
the pcNrf1-TK (Fig. 3-12, bar 7), which was on average 33% lower than the activity of the 
pcTCF11-TK plasmid. For amounts lower than 2.0 µg, the luciferase activities were not 
significantly higher than that of the empty vector, while higher amounts gave results with 
great deviation (not shown). 
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Figure 3-12 Luciferase induction in COS-1 cells transiently transfected with various amounts of low 
expressing TCF11/Nrf1 constructs:  0.2µg of the 3.2PBGDLuc reporter was co-transfected with either 0.8µg 
of the empty pcDNA3-TK vector (bar 1), or 0.8, 1.5 or 2.0µg of low expression TCF11/Nrf1 plasmids (bars 2 
through 7).  The total amount of transfected DNA was kept constant at 2.2µg by adding empty vector DNA (bars 
2 through 7). Luciferase activity was normalized and is relative to the activity given with the empty vector. The 
induction shown is the average of 3 experiments, and the error bars reflect the standard deviation of the mean 
value.  
 
3.2.3 Detection of TCF11/Nrf1 protein expression 
 
The transactivating abilities of the high and low expression plasmids were investigated 
through luciferase activity assays. The studies displayed that the high expression plasmids 
gave a higher luciferase activity than that of the low expression plasmids. In addition, TCF11-
containing plasmids gave higher activity compared to the Nrf1-containing plasmids, both for 
the low and the high expression plasmids.  
 
To examine if the observed differences in luciferase activity were directly related to the 
expression of TCF11/Nrf1 protein in the cells, COS-1 cells transfected with high or low 
TCF11/Nrf1 expressing plasmids were analyzed through Western blot analysis (section 2.3.3).  
The Western blot is shown in figure 3-13. The pcTCF11 vector (Fig. 3-13, lane 2) displayed 
three translational products marked with (*); two of which were large proteins of ~160kDa 
and 140kDa, and a smaller protein of 65kDa. In addition, three possible processing products 
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are marked with () and are of sizes 45kDa, 32kDa, and 28kDa. The blot of pcNrf1 (Fig. 3-
13, lane 3) displayed the same products, though the two large protein products appeared 
slightly smaller. There was no significant quantitative difference in the expression of TCF11 
and Nrf1 proteins for the high expression vectors. However, the high expression vectors 
displayed a 2-3 times increase in expression of TCF11/Nrf1 proteins when compared to the 
low expression plasmids (Fig. 3-13, lanes 5 and 6). The protein expression displayed by the 
low expression constructs was too low to detect the putative difference between TCF11 and 
Nrf1. Also noticeable is the high background, represented by the bands present in the 
pcDNA3 and pcDNA3-TK control lanes (lanes 1 and 4, respectively). 
 
 
Figure 3-13 Detection of translational products using Western blot analysis: Whole cell extracts were 
prepared from COS-1 cells transiently transfected with 0.8µg of high and 2.0µg of low TCF11/Nrf1 expression 
constructs. After SDS-PAGE and transfer to a PVDF membrane, immunodetection with a 1:1000 dilution of the 
primary polyclonal antibody rabbit anti-Nrf1 and a 1:2000 dilution of the secondary antibody donkey anti-rabbit 
AP-conjugate revealed the different translational products (*), and possible processing products (). The 
numbers on the left represent the size of the protein marker (M) in kDa. Extracts of cells transfected with 
pcDNA3 and pcDNA3-TK show background staining with this antibody. Expression from the transfected 
constructs is seen in addition to this background pattern. 
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3.2.4 Intracellular localization of TCF11 and Nrf1 proteins 
 
To determine the intracellular localization of the TCF11 and Nrf1 proteins, high expression 
and low expression plasmids were transfected into COS-1 cells and prepared for 
immunocytochemistry (section 2.3.4) through cell fixation and labeling (section 2.3.4.1). 
Images were acquired through epifluorescence microscopy (section 2.3.4.2).  
 
The epifluorescence microscopy images (Fig. 3-14) displayed high background staining, 
represented by the images of the pcDNA3-transfected control cells (Fig. 3-14, A). This 
complicated the intracellular localization of the TCF11 protein because it was difficult to 
distinguish the TCF11 from the background in the transfected cells expressing TCF11 
(represented by Fig. 3-14 B []).  
 
 
 
 
Figure 3-14 Epifluorescence microscopy studies of transiently transfected COS-1 cells: COS-1 cells were 
transiently transfected with 0.8 µg of high and low TCF11/Nrf1 expressing plasmids. Cells were fixed and 
stained with 1:1000 dilution of the primary Ab rabbit -Nrf1, followed by 1:330 dilution of the fluorescence 
isothiocyanate (FITC) conjugated secondary Ab anti-rabbit IgG. Images were acquired with an epifluorescence 
microscope using a blue filter to detect FITC. The images displayed are pcDNA3 (A) and pcTCF11 (B) 
transfected cells, while the remaining images are not shown. Transfected cells are marked with (). Images of 
cells transfected with pcDNA3 show background staining with this antibody. 
 
The high background staining was caused by low specificity of the primary Ab since 
pcTCF11 transfected COS-1 cells stained directly with the secondary Ab did not reveal any 
background staining (not shown). A different primary antibody, the -TCF11 (53), was 
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acquired and used along with the secondary Ab to label pcTCF11 transfected COS-1 cells. To 
find the optimal Ab dilution, the transfected cells were stained with a variety of Ab 
concentrations.   
 
The images acquired for the Ab optimalization test (Fig. 3-15) displayed that COS-1 cells 
stained with a 1:10000 dilution of primary Ab and a 1:330 dilution of secondary Ab (panel C) 
produced the strongest signal with the least amount of background. Higher dilutions of the 
primary antibody were attempted, but did not give detectable signals (not shown). 
 
 
Figure 3-15 Epifluorescence microscopy studies of Ab-optimalization study:  COS-1 cells were transiently 
transfected with 0.8 µg of pcTCF11 plasmid. Cells were fixed and stained with various dilutions of the primary 
Ab rabbit -TCF11, followed by various dilutions of the fluorescence isothiocyanate (FITC) conjugated 
secondary Ab anti-rabbit IgG. Panels A-C displays cells stained with 1:2000, 1:5000 and 1:10000 of the 1ºAb 
along with 1:330 of the 2ºAb, respectively, while cells in panels D-F were stained with 1:2000, 1:5000 and 
1:10000 of 1ºAb, along with 1:2000 of 2ºAb, respectively. Images were acquired with an epifluorescence 
microscope using a blue filter to detect FITC. 
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Epifluorescence microscopy images of the high and low TCF11/Nrf1 expressing plasmids by 
using the optimized dilution of the antibodies are shown in figure 3-16. The images of the 
high expression plasmids (Fig. 3-16, panes A and B) showed that TCF11 was located 
throughout the cells transfected with the pcTCF11 plasmid (Fig. 3-16, panes A1-A3). 
Similarly, the pcNrf1-transfection localized Nrf1 throughout the cell as well, (Fig. 3-16, panes 
B1-B3), however there were smaller quantities in the cytoplasm. The images of the low 
expression plasmids (Fig. 3-16, panes C and D) gave the same indication with respect to 
localization, but this could not be said with certainty due to the weak FITC fluorescence. On 
the other hand, the differences in intensity showed that there were reduced amounts of 
TCF11/Nrf1 in the low expression constructs compared to the high expression constructs.  
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Figure 3-16  Epifluoresecence microscopy images of COS-1 cells transfected with pcTCF11, pcTCF11-TK, 
pcNrf1 and pcNrf1-TK: COS-1 cells were transiently transfected with 0.8 µg of (A) pcTCF11 and (B) pcNrf1 
plasmids, and 2.0 µg of (C) pcTCF11-TK and (D) pcNrf1-TK plasmids. Cells were fixed and stained with 
1:10000 dilution of the primary Ab rabbit -TCF11, followed by 1:330 dilution of the fluorescence 
isothiocyanate (FITC) conjugated secondary Ab anti-rabbit IgG. The cells were subsequently stained with 1 
µg/ml dilution of Hoechst 33342. Images were acquired with an epifluorescence microscope using a 40x/0.70 oil 
immersion objective, an F-view digital camera (Soft Imaging System), and a blue filter and UV-filter to detect 
FITC and Hoechst 33342, respectively. Images A1-D1 show the cells stained with Hoechst, images A2-D2 
display cells stained with FITC, while A3-D3 represent the merged images. 
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To obtain a more detailed picture of the intracellular localization of TCF11/Nrf1 for both the 
high and low expression plasmids, images of the transfected cells were acquired through 
confocal microscopy (section 2.3.4.3). The images acquired (Fig. 3-17) showed that TCF11 
was located in both the nucleus and cytoplasm in the pcTCF11 (Fig. 3-17, pane B) and 
pcTCF11-TK (Fig. 3-17, E) transfected cells. Similarly, the pcNrf1 transfected cells (Fig. 3-
17, C) displayed Nrf1 in the nucleus and cytoplasm. However, the cells transfected with 
pcNrf1-TK (Fig. 3-17, F) displayed strict nuclear localization of Nrf1. The images did not 
reveal additional compartmentalization for TCF11 or Nrf1, apart from their lacking in the 
nucleoli (). 
 
 
 
Figure 3-17 Confocal microscopy images of pcDNA3, pcDNA3-TK, pcTCF11, pcTCF11-TK, pcNrf1 and 
pcNrf1-TK: COS-1 cells were transiently transfected with 0.8 µg of (A) pcDNA3, (B) pcTCF11, and (C) 
pcNrf1 plasmids, and 2.0 µg of (D) pcDNA3-TK, (E) pcTCF11-TK, and (F) pcNrf1-TK plasmids. Cells were 
fixed and stained with 1:10000 dilution of the primary Ab rabbit -TCF11, followed by 1:330 dilution of the 
fluorescence isothiocyanate (FITC) conjugated secondary Ab anti-rabbit IgG. Images were acquired with a 
digital confocal laser-scanning microscope using a 100x/1.25 oil immersion objective, a TCS-SP digital scanning 
head, and a He/Ne/Ar laser lined at 488 nm for FITC excitation. The images of the pcDNA3 (A) and pcDNA3-
TK (D) transfected cells displays the background staining. One nucleolus is marked with ().  
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4 Discussion 
 
TCF11, along with its isoform Nrf1, belongs to the CNC-bZIP family of transcription factors. 
As mentioned earlier, the biological function of TCF11 and Nrf1 has yet to be determined, but 
their presence has been shown to be vital to embryonic development (60,61). Discovering the 
role of these transcription factors is therefore of great interest. The current vector system used 
to study TCF11 and Nrf1, however, has presented problems due to the high level of 
expression. One difficulty related to the over-expression of TCF11/Nrf1 is the observed cell-
toxicity (personal communication, C. Husberg), which prevents long-term studies. In addition 
to toxicity, the over-expression has also made detailed intracellular localization studies of the 
proteins difficult, necessitating the need for a plasmid construct that could express lower 
levels of TCF11/Nrf1. The goal of this project was therefore to study the activity and 
localization of the TCF11 and Nrf1 transcription factors in a low expression vector system. 
 
4.1 Transactivation assay of pTK, pTK-TCF11 and pTK-Nrf1 
 
The pRL-TK vector, containing the weak promoter HSV-TK, was decided to be a suitable 
low expression vector. The TCF11/Nrf1 gene would be inserted, replacing the Renilla 
luciferase (Rluc) gene, thus creating a weak TCF11/Nrf1 expressing plasmid. The excision of 
the Rluc gene was not a necessity since firefly luciferase and Rluc have different substrate 
specificities (92). However, it was completed in order to limit the size of the constructs, 
thereby simplifying the transfections. The creation of the pTK, pTK-TCF11, and pTK-Nrf1 
constructs was carried out as shown in figures 3-1 and 3-3.  
 
The transactivation measurements of the above constructs gave surprising results. COS-1 cells 
transiently transfected with the pTK-TCF11 and pTK-Nrf1 showed a 0.6 and 0.3 fold 
activation of luciferase, respectively, when compared to the pTK construct (Fig. 3-4). These 
results were unexpected given that pTK is a vector that, according to the technical 
specifications (93), should not express any products that may activate the reporter construct. 
However, cell lines contain numerous endogenous factors including transcription factors, co-
factors and other accessory factors that are potential reporter activators (94,95). In addition, 
the gene expression of the reporter construct is controlled by the PBGD promoter, which has 
been shown to be regulated by several factors other than TCF11/Nrf1 (35).  
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Therefore, the reporter induction might be caused by the presence of endogenous factors in 
the COS-1 cells.  However, the results (Fig. 3-5) showed that the transfection of the reporter 
construct alone did not give any noticeable luciferase activation, and the co-transfection with 
the empty pcDNA3 vector gave a very low activation of luciferase. In addition, the luciferase 
activity of pTK transfected cells increased considerably with increasing plasmid concentration 
and showed an activation that was 7.5 times higher compared to cells transfected with 
equivalent amounts of the pcDNA3 vector. Consequently, it appears as if the reporter 
induction is dependent on the presence of the pTK vector in addition to endogenous factors in 
the COS-1 cells.  
 
The pRL-TK vector is intended for use as an internal control in transfection assays to correct 
for variations in transfection efficiency (93). In order for the internal control to be reliable, the 
vector should be unaffected by the different experimental conditions. However, several 
reports have shown that pRL-TK is sensitive to numerous transcription factors, hormones, and 
inhibitor molecules that regulate the Rluc gene expression (94-99). The PPAR, HNF-4, 
COUP-TFI, and ARP-1 nuclear receptors all caused a repression of the pRL-TK luciferase 
expression when co-transfected in CV-1 cells (95). In contrast, the luciferase activity was 
elevated by the presence of dihydrotestosterone (DHT) in the same cell-line (94) and 12S 
E1A oncoprotein presence in Saos-2 cells (99). Hence, a possible reason for the observed high 
luciferase activity could be the result of the pRL-TK vector’s sensitivity to regulatory factors. 
This possible explanation is presented in figure 4-1. COS-1 cells, as mentioned earlier, 
contain numerous endogenous factors that may induce or repress the reporter. However, in the 
absence of the pRL-TK vector, the reporter was not activated. This inhibition may be caused 
by inactivating factor(s) binding to activating factor(s), thereby preventing luciferase 
activation (Fig 4-1 A-1). Another possibility could be that inhibiting factors bind to repressor 
sites on the reporter, preventing activating factors from inducing the reporter (Fig 4-1 B-1). 
Thus, if the pTK vector contains motifs that titer out these inhibiting factors, its presence may 
result in an increase in luciferase activation through the release of the activating factors (Fig. 
4-1 A-2), or the removal of the repressor factors (Fig. 4-1 B-2). 
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Figure 4-1 Theoretical models for the observed luciferase activation due to the presence of pTK.              
(A-1) Inhibiting and activating agents form a complex that cannot activate the pBGD (3.2PBGDLuc) reporter. 
(A-2) pTK binds the complex thereby releasing the activating factor, which subsequently induces the reporter.  
(B-1) Inhibiting factors bind to the reporter thereby preventing the induction by activating factors. (B-2) pTK 
binds and titers out the inhibiting factors, allowing for the activating factors to induce the reporter. 
 
The observed elevated luciferase activity caused by an increasing pTK concentration (Fig. 3-
5) supports the above mentioned theories. In these experiments a possible linear relationship 
between luciferase activity and pTK concentration could not be examined because the total 
DNA amount was not kept constant through the addition of an empty vector. This vector 
addition was excluded because different vectors have been seen to affect one another (100), 
which could have a detrimental effect on the experiment. This was also the reason why an 
internal control, which measures transfection efficiency, was excluded in favor of protein 
content normalization in combination with numerous experimental repeats. Although the 
latter method merely normalizes for sample loss during processing (101), transfections by 
means of FuGENE have previously been determined to be adequately stable (personal 
communication, C. Husberg). 
 
One way to identify the endogenous inhibitory and activating factors that potentially caused 
the observed luciferase activity could be to establish possible target binding sites within the 
vectors. The observation that the presence of TCF11/Nrf1 had a reducing effect on luciferase 
activation (Fig. 3-4) suggested that the cause of the induction is somehow related to proteins 
binding to the NF-E2/AP-1 site. This was supported by the results obtained from the 
luciferase assays involving the co-transfection of normal and mutated 3.2PBGDLuc reporter 
constructs with the pTK-TCF11 construct (Fig. 3-7). A theoretical model explaining the 
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observed results is presented in figure 4-2. The reduced activation due to the presence of 
TCF11 may indicate that TCF11 has a stronger binding affinity to the NF-E2/AP-1 site, but at 
the same time causes lower luciferase activation compared to the proposed endogenous 
factors (Fig. 4-2 B). The co-transfection with pTK-TCF11 and 3.2PBGDLuc Mut.1 reporter 
showed an induction equivalent to the pTK and wild type reporter co-transfection. This 
mutation, which has been shown to prevent TCF11 from binding to the NF-E2 site (55), 
would still allow AP-1 binding factors to bind (Fig. 4-2 C). However, the pTK-TCF11 and 
3.2PBGDLuc Mut.2 reporter co-transfection gave a luciferase activation that was reduced to 
that of the pTK-TCF11 and wild type reporter co-transfection. This mutation prevents not 
only TCF11, but also AP-1 binding factors, from binding to the NF-E2/AP-1 binding site (55) 
(Fig. 4-2 D). These results suggest that the presence of pTK makes AP-1 binding factors 
available to the AP-1 site in the promoter (Fig. 4-2 A). 
 
 
Figure 4-2 Theoretical model explaining the effects of the PBGD promoter mutation on luciferase 
activation.  (A) In the absence of TCF11, the endogenous factor(s) bind to the AP-1 site and cause high 
luciferase activity. (B) In the presence of TCF11 the endogenous factor(s) cannot bind to the AP-1 site and the 
activity is reduced. (C) When the NF-E2 site is mutated, TCF11 cannot bind, allowing endogenous factors to 
bind to the AP-1 site and activate the reporter. (D) When the AP-1 site mutation, neither factors can bind, 
resulting in reduced activity.  
 
However, even though the AP-1 site mutation resulted in decreased luciferase activation, it 
was still excessive compared to the activation caused by the presence of the pcDNA3 vector. 
This signified the existence of additional reporter activating and inhibiting factors in the COS-
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1 cells, and consequently additional binding motifs. By analyzing the sequences of pcDNA3, 
pTK and 3.2PBGDLuc constructs using the software program Motif 
(http://motif.genome.ad.jp), four different binding motifs where found that existed exclusively 
in the reporter plasmid and pRL-TK vector. The motifs bind LyF-1, TCF3, HNF-3 and Brn-
2 transcriptional regulators. None of the motifs were located in or near the PBGD promoter, 
however the TCF3, HNF-3 and Brn-2 are all located within the luciferase gene. This location 
may be of importance based on previous studies indicating the possibility that the regulation 
of the luciferase gene was dependent on interactions between nuclear receptors and the 
luciferase gene itself (95). If factors bound to the mentioned motifs have an inhibiting effect 
on the reporter, their binding to the motifs on the pTK may allow for reporter activation, 
supporting the theory presented in figure 4-1 B.  
 
The mentioned motifs’ importance in this luciferase assay is unknown. Nevertheless, their 
lacking in the inert pcDNA3 vector presents a possible explanation for the observed luciferase 
activity. Deleting or mutating the motifs in the pTK vector and observing the changes in 
luciferase activation could be an effective test to determine their importance. However, an 
important limitation in this approach is the presumed inability of the Motif software program 
to detect all possible motifs in the vectors. Furthermore, the models presented (Fig. 4-1 and 5-
2) may represent an over-simplification of the actual mechanisms. There may be numerous 
protein-protein interactions that ultimately result in the inhibition/activation of the reporter 
plasmid, as appear to be the situation for COUP-TFI activation of the vHNF-1 promoter (102) 
and HIV 1 LTR promoter (103).  
 
A possible strategy to avoid the observed pTK-caused induction, thereby enabling the use of 
the constructs, could be to utilize an alternative cell-line. Studies have shown that the 
activities of transcription factors are cell-line depend. The tk-CAT reporter containing the 
arrestin promoter was activated by the nuclear receptor ARP-1 in CV-1 cells, but unaffected 
in NG108 neuronal cells (104). In a different study, the COUP-TFI transcription factor 
induced a CAT reporter containing the mitochondrial 3-hydroxy-3-methylglutaryl-CoA 
synthase promoter in HepG2 cells, while the reporter activity was suppressed in R2C cells 
(105). However, due to the high sensitivity shown by pRL-TK in several cell lines, the 
success of this approach may have a high degree of uncertainty. 
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The reasons for the observed reporter induction by the presence of pTK may be numerous, 
and an interesting path to follow. However, the main objective of this thesis was to create and 
examine a plasmid expressing low levels of TCF11/Nrf1. Therefore, the investigation 
involving pTK was stopped at this point. 
 
4.2 Transactivation assay of pcTCF11-TK and pcNrf1-TK 
 
The alternative approach adopted due to the unwanted reporter induction, was to replace the 
strong promoter CMV in the pre-made pcDNA3 constructs with the weak promoter HSV-TK 
from the pRL-TK vector, thus transforming the plasmids into lower expressing constructs. 
The pcDNA3-TK, pcTCF11-TK and pcNrf1-TK constructs were created (Fig. 3-9). 
 
To ensure that the high luciferase activity seen for the pTK transfections did not occur for the 
pcDNA3-TK vector, the transactivating ability of the latter was established. The results 
showed that the luciferase induction was low and did not increase as the plasmid 
concentration increased (Fig. 3-10). This indicates that the HSV-TK promoter was not 
directly involved in the high induction of the reporter plasmid caused by the presence of the 
pTK vector (section 4.1).  
 
Subsequently, the transactivating abilities of the pcTCF11-TK and pcNrf1-TK plasmids were 
tested and compared to that of the high expression constructs pcTCF11 and pcNrf1 (Fig. 3-
11). The pcTCF11-TK and pcNrf1-TK constructs caused a ten-fold reduced induction 
compared to the pcTCF11 and pcNrf1, respectively, and were therefore termed ”low 
expression constructs”. However, the luciferase activities observed for the low expression 
constructs were not within the detection limits of the assay. To confirm that the constructs 
induced the reporter, the low expression plasmid concentration was increased from 0.8g to 
2.0µg (Fig. 3-12), which gave a luciferase activation that was three and a half times that of the 
background for the pcTCF11-TK transfection. Furthermore, the epifluorescence images (Fig. 
3-16) and the Western analysis (Fig. 3-13) supported the hypothesis that the observed 
decrease in luciferase activation for the low expression constructs were due to a lower protein 
concentration. The Western analysis revealed a two to three times lower expression of TCF11 
and Nrf1, which is in accordance to the observed luciferase activation where the low 
expression construct gave a ~2.8 times reduced induction compared to the high expression 
constructs. The Western gel also revealed several translational and processing products that 
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have previously been identified by our group (50). The large proteins of 160kDa and 140kDa 
represent the long active form of TCF11/Nrf1 whereas the 65kDa product represents the 
shorter inactive form of the proteins (49). These processing products have not been studied 
extensively. However, since the antibody utilized in this study is designed to recognize the C-
terminal end of TCF11/Nrf1, these products can be assumed to cover the C-terminal parts of 
the proteins. The observed high background staining could either indicate that the antibody 
showed low specificity, or high non-specific interaction. Unfortunately, the alternative 
antibody -TCF11 that was used for the intracellular localization studies (Section 3.2.4) was 
not used because stocks were depleted. 
 
4.2.1 Intracellular localization of TCF11 and Nrf1 
 
Previous studies on intracellular localization indicated that TCF11 had both a cytoplasmic and 
a nuclear localization, while Nrf1 was only found in the nucleus. This was found to be due to 
the absence of a functional NES-signal in Nrf1 (50). However, additional localization details 
were difficult to obtain due to the high expression of TCF11/Nrf1. It was therefore interesting 
to compare the high expression to the low expression constructs to see if a reduced amount of 
TCF11/Nrf1 could reveal additional information about their intracellular localization. 
 
The initial epifluorescence microscopy images did not reveal the intracellular localization of 
the proteins due to the excessive background shown by the commercial primary antibody 
(Fig. 3-14). A different primary antibody (Section 3.2.4) was therefore utilized following 
optimalization (Fig. 3-15). The subsequent images acquired by using epifluorescence 
microscopy (Fig. 3-16) supported the Western analysis results (Section 4.2), displaying a 
reduced level of expression of TCF11/Nrf1 for the low expression compared to the high 
expression constructs. The reduced level of TCF11/Nrf1 in the low expression construct cells, 
however, made intracellular localization difficult to determine from the acquired images. The 
images of the high expression constructs, on the other hand, revealed that both proteins were 
present in the cytoplasm and the nucleus, although the level of cytoplasmic Nrf1 were 
somewhat reduced. The subsequent confocal microscopy images (Fig. 3-17) gave similar 
results for the high expression constructs. However, the low expression constructs images 
displayed the presence of TCF11 in both the cytoplasm and the nucleus, while Nrf1 appeared 
to be strictly localized to the nucleus. This could indicate that the cytoplasmic Nrf1 seen in the 
high expression plasmid images could represent newly translated protein that had not yet 
Section 4            Discussion 
 
56 
trafficked to the nucleus, as was shown by Alefantis et al (106) with the cytoplasmic 
localization of the NES-mutated protein Tax.  
 
Additional compartmentalization of the proteins could not be detected, except for the absence 
of TCF11/Nrf1 in the nucleoli. 
 
4.2.2 Differences in TCF11 and Nrf1 activity 
 
Previous studies on the transactivating ability of Nrf1 and TCF11 have shown ambivalent 
results, with Nrf1 activity being similar to TCF11 in some cases (50), while displaying 
reduced activity compared to TCF11 in other studies (personal communication, E. Bjørgo). 
The results in this thesis supports the latter, with both the high and low Nrf1 expressing 
constructs displaying a reduction in luciferase activation when compared to that of TCF11 
expressing constructs (Fig. 3-11 and 3-12). pcTCF11 and pcTCF11-TK appeared to give on 
average 34% higher luciferase activation compared to that of pcNrf1 and pcNrf1-TK, 
respectively. These are surprising results seeing that strict nuclear localization of Nrf1 
(Section 4.2.1) would suggest an elevated activation compared to that of TCF11, due to 
increased availability to the target DNA. This could either indicate that the expression of 
Nrf1, or that its transactivating ability, was lower than that of TCF11. The Western analysis of 
parallel transfections did not reveal any significant deviation in the expression of the two 
proteins (Fig. 3-13). Furthermore, previous studies focusing on DNA binding ability did not 
present any significant differences between TCF11 and Nrf1 (50). This suggests that TCF11 
has a higher transactivating ability compared to Nrf1.  
 
One reason for the difference in the ability to transactivate may be due to the fact that 30 
amino acid residues are lacking from the AD in Nrf1. Studies have shown that proteins with 
increasing deletions of the AD sequences display a gradual loss of activity (107,108). The 
partial deletion of the main AD in Nrf1 may therefore pose an explanation to the reduction in 
activity.  
 
Another possible explanation for the elevated activity of TCF11 may be found in the 
regulating mechanism of nuclear export. The precise manner in which this mechanism is 
regulated has yet to be discovered for TCF11. However, one recognized way of regulating 
NES-dependent nuclear export is by means of phosphorylation (72,84,109-111). 
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Phosphorylation is predicted to cause conformational changes in the protein, thereby exposing 
NES and allowing for nuclear export (84,109,110). Studies on TCF11, on the other hand, have 
indicated that interference with several potent phosphorylation sites, including a serine rich 
region linked to the activation of TCF11, did not impede nuclear export (50). Still, there may 
be numerous alternative sites that are of importance, and studies have shown that activation-
related phosphorylation of a protein can be separate from the phosphorylation necessary to 
stimulate NES-related nuclear export (90,110). Therefore, suggesting that phosphorylation 
may be a prerequisite for nuclear export of TCF11 to occur, it is plausible that this modulation 
will take place for the isoform Nrf1 despite the absence of NES. This is supported by studies 
on the Snail transcription regulator (72), Smad4 protein (83), and the Smad1 protein (112), 
which showed that NES-related phosphorylation of proteins occurred independently of 
whether or not the NES signal was functional or mutated. The same studies reported further 
that the transactivating abilities of the mutated proteins were reduced, like that observed with 
Nrf1. In the case of the Snail transcription regulator, this reduction was explained by 
suggesting that the phosphorylated mutated protein retained its ability to bind DNA, while the 
ability to regulate the reporter was reduced (72). This could explain the observed decrease in 
activation that was non-attributable to the level of Nrf1 expression. Since the activity of Nrf1 
cannot be controlled by translocating out of the nucleus, like that seen for TCF11, 
phosphorylation may therefore act as a mechanism controlling the activity of Nrf1 by 
reducing its ability to activate the target promoters.  
 
Notably, an increased reduction of activation due to the suggested phosphorylation could be 
expected. However, in vivo, with endogenous levels of Nrf1 in a balanced situation, the 
regulatory system will not encounter Nrf1-expression of such magnitude like that seen when 
using the strong CMV promoter, or even the weaker HSV-TK promoter to control the 
expression. As an example, the N-WASP expressed under the CMV promoter was estimated 
to be 20-fold higher than that of endogenous N-WASP (109). Therefore, natural small 
changes in the availability of Nrf1 may therefore be controlled more efficiently by the 
proposed phosphorylation. 
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4.3 Conclusions 
 
The pRL-TK vector was deemed unreliable to be used as an expression vector for TCF11 
because its presence appeared to indirectly cause activation of the pBGD reporter vector. The 
manner in which this activation occurred is unknown, but it may be due to its reported high 
level of sensitivity towards endogenous factors. pRL-TK may titer out inhibiting factors, 
thereby allowing activating factors to gain access to and activate the reporter construct. This 
high sensitivity displayed by pTK towards another vector and/or endogenous factors 
emphasizes the caution that must be taken when using internal control plasmids to measure 
transfection efficiencies. 
 
The creation of pcDNA3-based constructs containing the HSV-TK promoter gave plasmids 
that expressed TCF11 and Nrf1 in lower amounts. These constructs may therefore elude the 
toxicity due to over-expression, allowing for prolonged studies of TCF11.  
 
The low expression constructs allowed for easier verification of the nuclear detainment of 
Nrf1, however additional intracellular compartmentalization was not observed. In addition, 
the transactivating ability of TCF11 was shown to be higher than Nrf1 in both the high and 
low expression constructs. 
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4.4 Future Aspects 
 
Initially, this thesis was meant to focus solely on constructing vectors that expressed reduced 
levels of TCF11 and Nrf1, and subsequently using these vectors to obtain information about 
the proteins’ localization, activation, and dimerization abilities. However, due to unexpected 
results, the use of pRL-TK (internal controls) in luciferase activation measurements was also 
examined. The reason behind the reporter plasmid induction caused by the presence of the 
pTK vector was left unanswered. However, studying the cause could be of high relevance to 
the scientific community, given that pRL-TK is intended for use as an internal control. If the 
reason for the induction is found, one could either alter the vector, thereby averting the 
problem, or make people aware of the potential problem associated with using pRL-TK with a 
similar transfectional set-up as presented in this thesis. 
 
The validity of the theory suggesting that the induction was caused by endogenous factors 
binding to pTK motifs could be investigated by deleting or mutating these motifs. If these 
sites did not prove to be of importance, a more extensive mutation/deletion study on pTK 
could be performed bearing in mind that the program Motif may omit motifs. Another option 
could be to co-transfect pTK and the reporter into alternative cell lines and subsequently 
observe if the variation of endogenous factors prevents the induction. 
 
The mortality rate of cells with lower expression of TCF11/Nrf1 was not studied due to time 
limitations. It could therefore be interesting to stably transfect cells with the low expression 
constructs and observe the viability of the cells.  
 
An interesting follow-up could also be to examine whether or not there exists a 
phosphorylation site that regulates both the nuclear export of TCF11 and activation of Nrf1. 
This could be revealed by extensively mutating or deleting potential phosphorylation sites in 
TCF11 and Nrf1, and subsequently observe the effects on the activity and localization of the 
proteins.  
 
The low expression plasmids could also be utilized to study what effect the presence of 
dimerization partners like MafG have on both gene expression and the intracellular 
localization of TCF11 and Nrf1. Reversely, it could be interesting to see if the presence of 
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TCF11 and Nrf1 causes differences in the intracellular localization of the dimerization 
partners due to the presence or absence of NES. It may therefore be necessary to construct 
low expression vectors of the dimerization partners to simplify the localization procedure. 
            References 
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